Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICE-MMD: NBP in Moyamoya Disease
NCT04205578Phase 3Unknown
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of butylphthalide in Moyamoya disease (2 arms). Primary endpoints: Perioperative ischemic stroke rate at 30 days, Perioperative death rate at 30 days and 1 more. Status: unknown.
02
Drugs
butylphthalide
03
Conditions
Moyamoya disease
Beyond the preview
Go deeper on NCT04205578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205578.